Suppr超能文献

相似文献

2
G9a/GLP Complex Maintains Imprinted DNA Methylation in Embryonic Stem Cells.
Cell Rep. 2016 Apr 5;15(1):77-85. doi: 10.1016/j.celrep.2016.03.007. Epub 2016 Mar 24.
3
G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment.
Genes Dev. 2012 Nov 15;26(22):2499-511. doi: 10.1101/gad.200329.112. Epub 2012 Oct 26.
4
Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Oncogene. 2009 Jan 15;28(2):184-94. doi: 10.1038/onc.2008.377. Epub 2008 Oct 13.
5
G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription.
EMBO J. 2008 Oct 22;27(20):2681-90. doi: 10.1038/emboj.2008.192. Epub 2008 Sep 25.
6
The polycomb group protein PCGF6 mediates germline gene silencing by recruiting histone-modifying proteins to target gene promoters.
J Biol Chem. 2020 Jul 10;295(28):9712-9724. doi: 10.1074/jbc.RA119.012121. Epub 2020 Jun 1.
7
A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP.
EMBO Rep. 2017 Aug;18(8):1442-1459. doi: 10.15252/embr.201744060. Epub 2017 Jun 14.
8
Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Mol Cell Biochem. 2014 Sep;394(1-2):23-30. doi: 10.1007/s11010-014-2077-4. Epub 2014 May 16.
10
Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis.
Am J Respir Cell Mol Biol. 2018 Apr;58(4):449-460. doi: 10.1165/rcmb.2017-0286OC.

引用本文的文献

2
Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome.
Mol Ther. 2024 Aug 7;32(8):2662-2675. doi: 10.1016/j.ymthe.2024.05.034. Epub 2024 May 24.
3
Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
J Med Chem. 2024 Apr 25;67(8):6397-6409. doi: 10.1021/acs.jmedchem.3c02394. Epub 2024 Apr 11.
4
Discovery of the First-in-class G9a/GLP PROTAC Degrader.
bioRxiv. 2024 Feb 29:2024.02.26.582210. doi: 10.1101/2024.02.26.582210.
6
Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer.
Cells. 2023 Mar 17;12(6):926. doi: 10.3390/cells12060926.
7
Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.
J Med Chem. 2022 Aug 11;65(15):10506-10522. doi: 10.1021/acs.jmedchem.2c00652. Epub 2022 Jun 28.
8
Augmenting engineered T-cell strategies in solid cancers through epigenetic priming.
Cancer Immunol Immunother. 2020 Nov;69(11):2169-2178. doi: 10.1007/s00262-020-02661-1. Epub 2020 Jul 10.
9
Epigenetic activation of POTE genes in ovarian cancer.
Epigenetics. 2019 Feb;14(2):185-197. doi: 10.1080/15592294.2019.1581590. Epub 2019 Mar 4.
10
Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets.
J Ovarian Res. 2019 Jan 4;12(1):1. doi: 10.1186/s13048-018-0475-z.

本文引用的文献

1
G9a/GLP complexes independently mediate H3K9 and DNA methylation to silence transcription.
EMBO J. 2008 Oct 22;27(20):2681-90. doi: 10.1038/emboj.2008.192. Epub 2008 Sep 25.
2
DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity.
EMBO J. 2008 Oct 22;27(20):2691-701. doi: 10.1038/emboj.2008.193. Epub 2008 Sep 25.
6
Unraveling epigenetic regulation in embryonic stem cells.
Cell Stem Cell. 2008 Feb 7;2(2):123-34. doi: 10.1016/j.stem.2008.01.005.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验